Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments
Introduction
Colloidal drug carriers such as liposomes and nanoparticles have been widely used for systemic drug delivery. Packaged into a nanocontainer, the drug is protected from chemical and enzymatic degradation. The first generation of nanocarriers, was developed 40 years ago. However, the carriers were rapidly eliminated from the bloodstream by the reticuloendothelial system (RES). Consequently, drug delivery could only reach the liver and spleen. In order to improve the vascular residence time of colloidal systems, hydrophilic and flexible polymers such as poly(ethylene) glycol (PEG) were grafted onto their surface, thus conferring steric protection [1]. Their main therapeutic application concerns drug delivery to tumor sites by way of the enhanced permeability and retention effect (EPR effect) [2].
Lipid nanocapsules (LNC) [3] belong to this generation of stealth nanovectors. These colloidal carriers, in the nanometer size range, are produced using a solvent-free process with biocompatible excipients. They are made up of an oily core surrounded by a hydrophilic surfactant, Solutol® HS15 (70% PEG660 hydroxystearate and 30% free PEG660) conferring long-circulating properties [4] and inhibiting the P-glycoprotein efflux pump (P-gp) [5], [6]. LNC can be loaded with anti-cancer agents such as etoposide and paclitaxel and can thus efficiently deliver drugs to glioma cells [7], [8].
As with most stealth nanocarriers, the therapeutic limitation of LNC is due to their non-specificity and their inability to cross the weakly permeable endothelia. Thus, these nanovectors cannot be used for drug delivery to the central nervous system (CNS). The blood brain barrier (BBB), separating the blood and the cerebral parenchyma, is mainly composed of brain capillary endothelial cells (BCEC) sealed together by continuous, tight junctions, drastically decreasing its permeability. Given this context, the LNC used for active targeting were modified using site-specific ligands to allow drug delivery to the CNS. OX26 murine monoclonal antibodies (OX26 MAb) that recognize the transferrin receptor (TfR) were conjugated to LNC (OX26-immunonanocapsules). This antibody specifically targets the BCEC through a high concentration of TfR expressed on its luminal side [9] and is able to cross the BBB via a receptor-mediated transcytosis mechanism [10]. OX26 MAb binds to an extracellular domain of the TfR, distinct from the transferrin binding site, thus avoiding competition with the endogenous transferrin in the circulation system. Besides, the Fc part of the whole antibody is known to activate both the usual pathway of the complement system and the macrophage-bearing Fc receptors on their surface. Consequently, the conjugation of entire antibodies may significantly decrease the vascular residence time of immunonanocapsules [11]. Thus, OX26 MAb Fab’ fragments characterized by the absence of the Fc part, were also conjugated to LNC (Fab’-immunonanocapsules).
The feasibility and potential of this active targeting strategy using nanocarriers have already been demonstrated. OX26-immunoliposomes are promising novel vectors for the delivery of doxorubicin and daunomycine to the brain [12], [13]. OX26-PLA and OX26-chitosan nanoparticles [14], [15] were conceived successfully and the chitosan immunonanoparticles were able to reach the cerebral parenchyma.
To allow the covalent attachment of site-directed biomolecules, a bifunctional polymer, distearoylphosphatidylethanolamine–PEG2000–maleimide (DSPE–PEG2000–maleimide) was incorporated into the LNC shell. Maleimide functions react with sulfhydryl groups to form thioether bonds. In contrast to Fab’ fragments which bear thiol residues on the intra-heavy chain, this reaction requires the thiolation of OX26 MAb. Besides, the incorporation of DSPE–PEG2000–maleimide was performed using a post-insertion procedure. This method was initially developed for the pegylation of liposomes. It consists in incubating particles in a micellar solution of PEG lipids. During incubation, a temperature-induced transfer occurs between phospholipids located in the liposomal system and lipid-conjugated polymers. Uster et al. [16] demonstrated that the incorporation rate of PEG1900–DSPE into liposomes was close to the optimum value after a 1 h incubation period at 60 C.
This present work describes the synthesis of immunonanocapsules.
Firstly, incorporation of the DSPE–PEG2000–maleimide into an LNC shell was characterized using an interfacial model. The effects of both temperature and the interactions between the bifunctional polymer and the components located at the LNC surface were studied. As for liposomes, the presence of phospholipids at the interface was presumed necessary in order to facilitate the transfer of matter. Conversely, the presence of Solutol® HS15 generating a steric barrier around the nanocapsule could reduce the DSPE–PEG2000–maleimide insertion. The polymer was adsorbed at pure O/W interface and on interfacial monolayers composed of Lipoïd® S75-3 or/and Solutol® HS15, using a drop tensiometer. The superficial pressures were measured at 25 and 60 °C for a 2 h-adsorption period and after cooling from 60 to 25 °C. The rheological behavior of these films was then determined using the generalized Maxwell model in order to identify the quality of the bifunctional polymer anchorage. This was to help determine whether or not the DSPE–PEG2000–maleimide could bear whole OX26 MAb and Fab’ fragments without desorption.
Secondly, we developed the conjugation of biomolecules on LNC. Thiolation and fragmentation of MAb were performed to covalently attach antibodies and Fab’ fragments onto the LNC surface. The influence of this chemical treatment on the recognition activity of biomolecules was studied by flow cytometry. The immunonanocapsules were then characterized by assessing the ligand density and measuring the size. Finally, their ability to target cells overexpressing TfR was verified by flow cytometry.
Section snippets
Reagents
Lipoïd® S75-3 (soybean lecithin at 69% of phosphatidylcholine and 10% phosphatidylethanolamine) and the nonionic hydrophilic surfactant Solutol® HS15 were kindly supplied by Lipoïd GmbH (Ludwigshafen, DE) and BASF (Ludwigshafen, DE), respectively. The lipophilic Labrafac® WL 1349 (caprylic–capric acid triglycerides) was generously provided by Gattefossé S.A. (Saint-Priest, FR). Due to the complex composition of these products, they will henceforth be referred to by their brand names (Lipoïd®,
Characterization of the post-insertion of DSPE–PEG2000–maleimide into an LNC shell
To allow the conjugation of site-specific ligands, LNC were functionalized with a maleimide sulfhydryl-reactive group using a post-insertion procedure. In order to study both the parameters playing a major role in the DSPE–PEG2000–maleimide adsorption and the stability of polymeric coating, an interfacial model was developed by a drop-rising technique.
Conclusions
Two novel types of immunonanocapsules were developed by conjugation of thiolated OX26 MAb and Fab’ fragments to LNC. The coupling of site-directed ligands required two steps. The first one was the incorporation of DSPE–PEG2000–maleimide into an LNC shell by a post-insertion procedure. An interfacial model showed that heating promotes the anchorage of DSPE–PEG2000–maleimide in the oil via its hydrophobic part. Besides, the polymeric coating was characterized by an elastic behavior and
Acknowledgments
We would like to thank Myriam Moreau (Inserm U646, Angers, France) for her technical assistance. We are also grateful to Dr. Catherine Guillet (Service Commun de Cytométrie et d’Analyse Nucléotique, Angers, France) for her skillful technical support. This work was supported by the Association pour la Recherche sur le Cancer and by the departmental committee of Maine-et-Loire of the Ligue contre le Cancer.
References (39)
- et al.
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties
Progr Lipid Res
(2003) - et al.
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
J Control Release
(2000) - et al.
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition
J Control Release
(2006) - et al.
Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time
FEBS Lett
(1996) - et al.
Method for the estimation of poly(ethylene glycol) in plasma protein fractions
Anal Biochem
(1980) - et al.
Optimization of oxidation of glycoproteins: an assay for predicting coupling to hydrazide chromatographic supports
J Chromatogr A
(1991) Tissue sulfhydryl groups
Arch Biochem Biophys
(1959)- et al.
Micromethod for quantification of SH groups generated after reduction of monoclonal antibodies
Nucl Med Biol
(1996) - et al.
Reorganization of lipid nanocapsules at air-water interface: I. Kinetics of surface film formation
Colloids Surf B: Biointerf
(2005) - et al.
Properties of polyethylene glycol 660 12-hydroxy stearate at a triglyceride/water interface
Int J Pharmaceut
(2002)